HC Wainwright Estimates Innoviva’s Q4 Earnings (NASDAQ:INVA)

Innoviva, Inc. (NASDAQ:INVA) – Equities researchers at HC Wainwright lowered their Q4 2025 earnings per share (EPS) estimates for shares of Innoviva in a research report issued on Monday, November 10th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn $0.48 per share for the quarter, down from their prior forecast of $0.54. HC Wainwright currently has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for Innoviva’s current full-year earnings is $0.33 per share. HC Wainwright also issued estimates for Innoviva’s Q1 2026 earnings at $0.45 EPS, Q3 2026 earnings at $0.57 EPS and FY2026 earnings at $2.23 EPS.

Innoviva (NASDAQ:INVA) last posted its earnings results on Wednesday, November 5th. The biotechnology company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.62. The company had revenue of $107.80 million for the quarter, compared to analyst estimates of $91.31 million. Innoviva had a return on equity of 18.67% and a net margin of 10.44%.

Several other equities research analysts also recently weighed in on INVA. Zacks Research downgraded shares of Innoviva from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Wall Street Zen raised Innoviva from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 25th. Oppenheimer assumed coverage on Innoviva in a research note on Monday, August 11th. They set an “outperform” rating and a $45.00 target price on the stock. Weiss Ratings upgraded Innoviva from a “hold (c)” rating to a “buy (b-)” rating in a research note on Friday, November 7th. Finally, Cantor Fitzgerald raised their price target on Innoviva from $29.00 to $31.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Innoviva presently has an average rating of “Moderate Buy” and a consensus price target of $38.60.

Innoviva Stock Up 1.7%

Shares of Innoviva stock opened at $22.28 on Wednesday. The company has a quick ratio of 2.44, a current ratio of 2.64 and a debt-to-equity ratio of 0.36. The company has a market cap of $1.40 billion, a P/E ratio of 71.87 and a beta of 0.42. The firm’s 50 day moving average price is $18.69 and its 200-day moving average price is $19.32. Innoviva has a 52-week low of $16.52 and a 52-week high of $22.46.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. lifted its holdings in shares of Innoviva by 2.6% during the first quarter. Principal Financial Group Inc. now owns 305,476 shares of the biotechnology company’s stock worth $5,538,000 after purchasing an additional 7,700 shares during the period. Victory Capital Management Inc. lifted its stake in Innoviva by 132.4% during the 1st quarter. Victory Capital Management Inc. now owns 412,281 shares of the biotechnology company’s stock valued at $7,475,000 after acquiring an additional 234,898 shares during the period. Bailard Inc. purchased a new stake in shares of Innoviva in the 1st quarter valued at $189,000. Denali Advisors LLC increased its stake in shares of Innoviva by 6.3% in the first quarter. Denali Advisors LLC now owns 376,606 shares of the biotechnology company’s stock worth $6,828,000 after acquiring an additional 22,282 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Innoviva in the first quarter worth $627,000. 99.12% of the stock is currently owned by hedge funds and other institutional investors.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.